Prior studies showed Rev-erbα agonists exhibited target-specific regulation of inflammatory response; for example, GSK4112 treatment suppressed LPS-induced IL-6 release in human myelomonocytic THP-1 cells in vitro, and SR9009 treatment reduced pro-inflammatory cytokine/chemokine IL-17A and IFN-γ in an experimental autoimmune encephalomyelitis mouse model in vivo [20,23]. This evidence concerns the gene IL17A and experimental autoimmune encephalomyelitis.